ABSTRACT
A series of 1-(1-indolinyl)-2-propylamines was synthesised and evaluated as 5-HT(2C) receptor agonists for the treatment of obesity. The general methods of synthesis of the precursor indoles are described. The functional efficacy and radioligand binding data for all of the compounds at 5-HT(2) receptor subtypes are reported. A number of compounds were found to reduce food intake in rats after oral administration.
Subject(s)
Anti-Obesity Agents/pharmacology , Indoles/pharmacology , Serotonin 5-HT2 Receptor Agonists , Serotonin Receptor Agonists/pharmacology , Animals , Anti-Obesity Agents/chemistry , Indoles/chemistry , RatsABSTRACT
During a program to investigate the biochemical basis of side effects associated with the antimalarial drug mefloquine, the authors made the unexpected discovery that the (-)-(R,S)-enantiomer of the drug is a potent adenosine A2A receptor antagonist. Although the compound was ineffective in in vivo animal models of central adenosine receptor function, it provided a unique nonxanthine adenosine A2A receptor antagonist lead structure and encouraged the initiation of a medicinal chemistry program to develop novel adenosine A2A antagonists for the management of Parkinson's disease (PD). The authors have synthesized and screened more than 2,000 chemically diverse and novel adenosine A(2A antagonists. Early examples from two distinct chemical series are the thieno[3,2-dy]pyrimidine VER-6623 and the purine compounds VER-6947 and VER-7835, which have high affinity at adenosine A2A receptors (K(i) values 1.4, 1.1, and 1.7 nmol/L, respectively) and act as competitive antagonists. In particular, VER-6947 and VER-7835 demonstrate potent in vivo activity reversing the locomotor deficit caused by the D2 receptor antagonist haloperidol, with minimum effective doses comparable with that of KW6002 (0.3 to 1 mg/kg). In conclusion, the authors have discovered potent, selective, and in vivo active nonxanthine adenosine A2A antagonists that have considerable promise as a new therapy for PD.
Subject(s)
Adenosine A2 Receptor Antagonists , Adenosine/analogs & derivatives , Antiparkinson Agents/therapeutic use , Parkinsonian Disorders/drug therapy , Purines/therapeutic use , Pyrimidines/therapeutic use , Adenosine/chemistry , Adenosine/therapeutic use , Animals , Antiparkinson Agents/chemistry , Binding, Competitive/drug effects , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Design , Drug Evaluation, Preclinical , Humans , Ligands , Mefloquine/chemistry , Mefloquine/therapeutic use , Mice , Motor Activity/drug effects , Neuroprotective Agents/chemistry , Neuroprotective Agents/therapeutic use , Parkinsonian Disorders/chemically induced , Phenethylamines/chemistry , Phenethylamines/therapeutic use , Purines/chemistry , Pyrimidines/chemistry , Radioligand Assay , Rats , Triazines/chemistry , Triazines/therapeutic use , Triazoles/chemistry , Triazoles/therapeutic useSubject(s)
Antioxidants/chemical synthesis , Free Radical Scavengers/chemical synthesis , Lipid Peroxidation/drug effects , Neuroprotective Agents/chemical synthesis , Oxidative Stress/drug effects , Pyridones/chemical synthesis , Animals , Antioxidants/chemistry , Antioxidants/pharmacology , Brain/cytology , Brain/drug effects , Brain/metabolism , Drug Evaluation, Preclinical , Free Radical Scavengers/chemistry , Free Radical Scavengers/pharmacology , In Vitro Techniques , Iodoacetates , Neuroprotective Agents/chemistry , Neuroprotective Agents/pharmacology , Pyridones/chemistry , Pyridones/pharmacology , Rats , Structure-Activity RelationshipABSTRACT
1. The aim of the study was to compare the effects of 14 day subcutaneous infusion of the 5-HT(2C) receptor agonists, m-chlorophenylpiperazine (mCPP, 12 mg kg(-1) day(-1)) and Ro 60-0175 (36 mg kg(-1) day(-1)) and the 5-HT releasing agent and re-uptake inhibitor, d-fenfluramine (6 mg kg(-1) day(-1)), on food and water intake, body weight gain and locomotion in lean male Lister hooded rats. 2. Chronic infusion of all three drugs significantly reduced food intake and attenuated body weight gain. In contrast, drug infusion did not lead to significant reductions in locomotor activity in animals assessed 2 and 13 days after pump implantation. 3. In a subsequent 14 day study that was designed to identify possible tolerance during days 7 - 14, animals were given a subcutaneous infusion of mCPP (12 mg kg(-1) day(-1)) or d-fenfluramine (6 mg kg(-1) day(-1)) for either 7 or 14 days. During the first 7 days both drugs significantly reduced body weight gain compared to saline-infused controls; however, from day 7 onwards animals withdrawn from drug treatment exhibited an increase in body weight such that by day 14 they were significantly heavier than their 14-day drug-treated counterparts. 4. Both mCPP and d-fenfluramine reduced daily food intake throughout the infusion periods. For 14-day treated animals this hypophagia was marked during the initial week of the study but only minor during the second week. In light of the sustained drug effect on body weight, the data suggest that weight loss by 5-HT(2C) receptor stimulation may be only partly dependent on changes in food consumption and that 5-HT(2C) receptor agonists may have effects on thermogenesis. 5. These data suggest tolerance does not develop to the effects of d-fenfluramine, mCPP and Ro 60-0175 on rat body weight gain.
Subject(s)
Body Weight/drug effects , Drinking/drug effects , Eating/drug effects , Motor Activity/drug effects , Serotonin Agents/pharmacology , Analysis of Variance , Animals , Ethylamines/pharmacology , Fenfluramine/pharmacology , Hypothalamus/drug effects , Hypothalamus/metabolism , Indoles/pharmacology , Infusion Pumps , Piperazines/pharmacology , RNA, Messenger/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Receptor, Serotonin, 5-HT2C , Receptors, Serotonin/genetics , Time FactorsABSTRACT
The neuroprotective efficacy of antioxidant molecules against iodoacetate (IAA) neurotoxicity in rat cerebellar granule cell (CGC) cultures was investigated. Transient exposure to IAA caused a concentration-dependent decrease in cell viability (ED50 = 9.8 microM). Dizocilpine maleate (MK-801), and 1,2,3,4-tetrahydro-6-nitro-2,3-dioxobenzo[f]quinoxaline-7-sulfonamide (NBQX), failed to prevent IAA toxicity. Certain antioxidant molecules were shown to be neuroprotective against IAA when combined with MK-801 but were ineffective when administered alone. (S)-(-)-Trolox, butylated hydroxytoluene (BHT), and U-83836E exhibited EC50 values of 78, 5.9, and 0.25 microM, respectively, in the presence of 10 microM MK-801. IAA also induced an increase in intracellular oxidative stress, which was quenched by the antioxidants (in the presence of MK-801) in cultures loaded with the oxidant sensitive dye 2'7'-dichlorodihydrofluorescein diacetate (DCFH-DA).
Subject(s)
Antioxidants/pharmacology , Cerebellar Cortex/drug effects , Iodoacetates/toxicity , Neuroprotective Agents/pharmacology , Neurotoxins/toxicity , Receptors, N-Methyl-D-Aspartate/drug effects , Animals , Butylated Hydroxytoluene/pharmacology , Cells, Cultured , Cerebellar Cortex/cytology , Chromans/pharmacology , Dizocilpine Maleate/pharmacology , Dose-Response Relationship, Drug , Drug Synergism , Fluoresceins/metabolism , Fluorescent Dyes/metabolism , Oxidative Stress , Piperazines/pharmacology , Quinoxalines/pharmacology , Rats , Rats, Sprague-DawleyABSTRACT
We reevaluate here an earlier report of monosaccharide binding by the C-type lectin-like, leukocyte surface protein CD69 in the form of a recombinant soluble dimer, and we examine polysaccharide binding by the protein. We have expressed in Escherichia coli a new construct of the extracellular part (Q(65)-K(199)) of human CD69. We describe the folding in vitro to produce, in good yield, the protein in a soluble, disulphide-linked, dimeric form, and the results of binding experiments with monosaccharides: glucose, galactose, mannose, fucose, N-acetylglucosamine, and N-acetylgalactosamine, linked to bovine serum albumin. Monosaccharide-binding signals are not detectable. Among the polysaccharides, heparin, chondroitin sulphates A, B, and C, fucoidan, and dextran sulphate, CD69 dimer gives a weak binding signal with fucoidan.
Subject(s)
Antigens, CD/metabolism , Antigens, Differentiation, T-Lymphocyte/metabolism , Escherichia coli/genetics , Monosaccharides/metabolism , Recombinant Fusion Proteins/metabolism , Amino Acid Sequence , Antigens, CD/biosynthesis , Antigens, CD/chemistry , Antigens, CD/isolation & purification , Antigens, Differentiation, T-Lymphocyte/biosynthesis , Antigens, Differentiation, T-Lymphocyte/chemistry , Antigens, Differentiation, T-Lymphocyte/isolation & purification , Binding Sites , Blotting, Western , Dimerization , Disulfides/metabolism , Epitopes/biosynthesis , Epitopes/chemistry , Epitopes/isolation & purification , Epitopes/metabolism , Humans , Hydrogen-Ion Concentration , Lectins, C-Type , Molecular Sequence Data , Molecular Weight , Peptide Fragments/biosynthesis , Peptide Fragments/chemistry , Peptide Fragments/isolation & purification , Peptide Fragments/metabolism , Polysaccharides/metabolism , Protein Binding , Protein Denaturation , Protein Folding , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/isolation & purification , SolubilityABSTRACT
1. The goal of this study was to characterize the agonist pharmacology of human 5-HT2A, 5-HT2B and 5-HT2C (VSV) receptors expressed in CHO-K1 (Chinese hamster ovary) cells. 2. We used a fluorometric imaging plate reader (FLIPR) which allows rapid detection of rises in intracellular calcium levels upon the addition of agonists. 3. Stimulation of all three receptors by 5-HT caused a robust concentration dependent increase in intracellular calcium levels. No such effect was observed from non-transfected control CHO-K1 cells. 4. The rank order of potency of agonists at the different receptor subtypes varied. Tryptamines, BW-723C86, d-norfenfluramine, Ro 60-0175 and LSD exhibited the following rank order of potency; 5-HT2B>5-HT2C>5-HT2A. Piperazines such as m-Chlorophenylpiperazine (mCPP), ORG-12962, MK-212 and also ORG-37684 exhibited a rank order of potency of 5-HT2C>5-HT2B>5-HT2A. The phenylisopropylamines DOI and DOB had a rank order of 5-HT2A>5-HT2B>5-HT2C. 5. Many agonists tested had partial agonist actions when compared to 5-HT, and a wide range of relative efficacies were exhibited, which was cell line dependent. For example, mCPP had a relative efficacy of 65% at 5-HT2C receptors but <25% at either 5-HT2A or 5-HT2B receptors. 6. Interpretation of literature values of functional assays using different cell lines, different receptor expression levels and different receptor isoforms, is complex. Species differences and the previous use of antagonist radioligands to characterize agonist potency in binding assays emphasizes the importance of studying agonists in the same experiment using the same assay conditions and parental cell lines.